22.04.2022 BB BIOTECH AG  CH0038389992

DGAP-Adhoc: BB Biotech AG publishes its interim report


 

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

22-Apr-2022 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
April 22, 2022

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2022 amounted to CHF 300 mn (profit of CHF 221 mn in the same period 2021). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2022 is available under report.bbbiotech.ch/Q122 or www.bbbiotech.com.


For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, [email protected]

www.bbbiotech.com

Company profile

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. BB Biotech relies on the long-standing experience of its distinguished Board of Directors and the investment research skills of the experienced investment management team of Bellevue Asset Management AG when making its investment decisions.


22-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1331939

 
End of Announcement DGAP News Service

1331939  22-Apr-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1331939&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 8,84 624,17 5,13 669,48 683,90 0,00 0,00
EBITDA1,2 -746,78 588,33 -418,21 624,04 637,31 -390,46 0,00
EBITDA-Marge3 -8.447,74 94,26 -8.152,24 93,21 93,19 0,00 0,00
EBIT1,4 -746,78 588,33 -418,21 624,04 637,31 -390,46 0,00
EBIT-Marge5 -8.447,74 94,26 -8.152,24 93,21 93,19 0,00 0,00
Jahresüberschuss1 -747,71 587,80 -418,27 622,84 637,24 -390,53 0,00
Netto-Marge6 -8.458,26 94,17 -8.153,41 93,03 93,18 0,00 0,00
Cashflow1,7 107,46 225,26 95,66 197,69 241,97 -91,44 0,00
Ergebnis je Aktie8 -13,51 10,62 -7,55 11,24 11,51 -7,05 -5,00
Dividende8 2,58 2,85 2,68 3,20 3,32 3,67 1,25
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 60,100 Kaufen 3.329,54
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
16,69 4,18 4,04 10,73
KBV KCV KUV EV/EBITDA
1,44 - 0,00 -4,96
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,25 1,50 2,08 23.03.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
22.04.2022 22.07.2022 21.10.2022 17.02.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,31% 2,56% -18,84% -15,35%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei EQS abrufen


Biotechnologie , A0NFN3 , BBZA , XETR:BBZA